| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 1,032,096 | 700,202 | 484,381 | 370,951 |
| Costs of sales | 406,721 | 159,350 | 121,021 | 100,504 |
| Gross profit | 625,375 | 540,852 | 363,360 | 270,447 |
| Selling, general and administrative | 1,165,517 | 1,192,874 | 1,108,507 | 847,820 |
| Total operating expenses | 1,165,517 | 1,192,874 | 1,108,507 | 847,820 |
| Loss from operations | -540,142 | -652,022 | -745,147 | -577,373 |
| Interest income (expense), net | 409 | 1,153 | -1,595 | -794 |
| Other income | 1,814 | 1,180 | 614 | - |
| Total other income (expenses) | 2,223 | 2,333 | -981 | -794 |
| Net loss | -537,919 | -649,689 | -746,128 | -578,167 |
| Basic and diluted (in dollars per share) | -0.01 | -0.01 | -0.02 | -0.01 |
| Basic and diluted (in shares) | 47,539,384 | 46,823,111 | 46,816,114 | 45,613,912 |
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)